title: Prediction of hepatic fibrosis in patients coinfected with HIV and hepatitis C virus based on genetic markers.
abstract: OBJECTIVE
  To assess the ability of the cirrhosis risk score (CRS) to predict liver fibrosis progression in HIV/hepatitis C virus (HCV)-coinfected patients.
  
  
  METHODS
  Retrospective follow-up study.
  
  
  METHODS
  Based on a minimum follow-up time of 10 years with HCV infection, 190 HIV/HCV-coinfected patients were classified according to their METAVIR score: (1) 25 nonprogressor patients who did not develop fibrosis (F0) and (2) 165 progressor patients who developed fibrosis (F ≥ 1). Seven polymorphisms of CRS signature and IL28B genotype were performed using the GoldenGate assay. The CRS signature was calculated by naive Bayes formula as previously described.
  
  
  RESULTS
  Nonprogressors had CRS values significantly lower than progressors (0.61 versus 0.67; P = 0.043). Among the progressors, we observed similar CRS values through all the fibrosis stages (F1/F2/F3/F4). The percentage of patients with CRS > 0.70 (high risk of developing fibrosis) was higher in progressors than in nonprogressors; but the percentages with values between 0.50 and 0.70 (intermediate risk) and <0.50 (low risk) were quite similar for each of the fibrosis stages (P = 0.047). The area under the receiver-operating characteristic curve of CRS for discriminating nonprogressor versus progressor was 0.625 (P = 0.043). When clinical variables were considered (age at HCV infection, intravenous drug use, gender, IL28B, and HCV genotype), the area under the receiver-operating characteristic curve of CRS improved up to 0.739 (P < 0.001).
  
  
  CONCLUSIONS
  CRS itself seems not to be a good marker for identifying HIV/HCV-coinfected patients who are at high risk of developing liver fibrosis. However, CRS score coupled with clinical factors might help to distinguish between nonprogressors and progressors patients.
authors.affiliation: *Viral Infection and Immunity Unit, National Centre of Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain; †Infectious Diseases and HIV Unit, Hospital General Universitario Gregorio Marañón, Madrid, Spain; ‡Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain; and Departments of §Internal Medicine; ‖Pathology, Hospital General Universitario, Gregorio Marañón, Madrid, Spain.
authors.forename: Amanda
authors.initials: A
authors.lastname: Fernández-Rodríguez
authors.forename: Juan
authors.initials: J
authors.lastname: Berenguer
authors.forename: María A
authors.initials: MA
authors.lastname: Jiménez-Sousa
authors.forename: María
authors.initials: M
authors.lastname: Guzmán-Fulgencio
authors.forename: Dariela
authors.initials: D
authors.lastname: Micheloud
authors.forename: Pilar
authors.initials: P
authors.lastname: Miralles
authors.forename: Juan Carlos
authors.initials: JC
authors.lastname: López
authors.forename: José María
authors.initials: JM
authors.lastname: Bellón
authors.forename: Teresa
authors.initials: T
authors.lastname: Aldamiz-Echevarria
authors.forename: Pilar
authors.initials: P
authors.lastname: García-Broncano
authors.forename: Ana
authors.initials: A
authors.lastname: Carrero
authors.forename: Emilio
authors.initials: E
authors.lastname: Alvarez
authors.forename: Salvador
authors.initials: S
authors.lastname: Resino
mesh_terms: D000293:Adolescent; D000328:Adult; D060085:Coinfection / Q000150:complications; D005260:Female; D005500:Follow-Up Studies; D005819:Genetic Markers; D015658:HIV Infections / Q000150:complications*; D019698:Hepatitis C, Chronic / Q000150:complications*; D006801:Humans; D008103:Liver Cirrhosis / Q000175:diagnosis* / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide; D011379:Prognosis; D012189:Retrospective Studies; D055815:Young Adult
chemical_list: D005819:Genetic Markers